Abstract: A turbomachine compressor module, comprising an annular array of structural arms defining inter-arm spaces between two circumferentially adjacent arms; and an annular array of stator vanes with variable orientation about a respective axis (A) and disposed at least partially within the inter-arm spaces. The arms are provided with flaps pivotable about a respective axis (B). Also, a turbomachine provided with such a module and a row of rotor blades directly downstream of the module.

Abstract: The compounds of the present invention are represented by the following compounds having Formula I and Formula (I?): where the substituents R1, R2, R2?, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: The compounds of the present invention are represented by the following compounds having Formula I and Formula (I?): where the substituents R1, R2, R2?, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: Improved virtual collaboration environments allow participants in a primary collaboration session to initiate side conversations with fellow participants based on virtual locations of each participant within a virtual collaboration layout. The virtual collaboration layout defines virtual locations of each participant in the collaboration session. If a virtual distance between two participants a below a threshold, the participants are able to engage in a side conversation. Management information is provided to a collaboration session host. The management information indicates, for example, a volume or frequency of communication occurring on each side conversation, or an elapsed time since the side conversation was initiated.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3, R4, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: Improved virtual collaboration environments allow participants in a primary collaboration session to initiate side conversations with fellow participants based on virtual locations of each participant within a virtual collaboration layout. The virtual collaboration layout defines virtual locations of each participant in the collaboration session. If a virtual distance between two participants a below a threshold, the participants are able to engage in a side conversation. Management information is provided to a collaboration session host. The management information indicates, for example, a volume or frequency of communication occurring on each side conversation, or an elapsed time since the side conversation was initiated.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I): where the substituents R, R1-R5, k, m, n, and q are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues.

Abstract: A turbomachine compressor module, comprising an annular array of structural arms defining inter-arm spaces between two circumferentially adjacent arms; and an annular array of stator vanes with variable orientation about a respective axis (A) and disposed at least partially within the inter-arm spaces. The arms are provided with flaps pivotable about a respective axis (B). Also, a turbomachine provided with such a module and a row of rotor blades directly downstream of the module.

Abstract: Improved virtual collaboration environments allow participants in a primary collaboration session to initiate side conversations with fellow participants based on virtual locations of each participant within a virtual collaboration layout. The virtual collaboration layout defines virtual locations of each participant in the collaboration session. If a virtual distance between two participants a below a threshold, the participants are able to engage in a side conversation. Management information is provided to a collaboration session host. The management information indicates, for example, a volume or frequency of communication occurring on each side conversation, or an elapsed time since the side conversation was initiated.

Abstract: The compounds of the present invention are represented by the following compounds having Formula I and Formula (I?): where the substituents R1, R2, R2?, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: The compounds of the present invention are represented by the following compounds having Formula I: where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): where the substituents R1-R4, Rx, Ry, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

Abstract: A conference system includes a controller and clusters of media nodes. Each media node performs media packet processing operations and connects with other media nodes and client devices. The controller sends to a client device contact information for candidate clusters. The controller receives from the client device a measure of reachability to each candidate cluster as determined by the client device using the contact information. The controller receives from the client device a request to join a communication session. Responsive to the request, the controller determines a best cluster among the candidate clusters to which the client should connect for the communication session based on the measures of reachability to the candidate clusters, and selects a media node in the best cluster. The controller sends to the client device contact information for the media node to enable the client device to connect to the media node for the communication session.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3, R4, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: The compounds of the present invention are represented by the following compounds having Formula I: where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): where the substituents R1-R4, Rx, Ry, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3 R4, R?, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: A conference system includes a controller and clusters of media nodes. Each media node performs media packet processing operations and connects with other media nodes and client devices. The controller sends to a client device contact information for candidate clusters. The controller receives from the client device a measure of reachability to each candidate cluster as determined by the client device using the contact information. The controller receives from the client device a request to join a communication session. Responsive to the request, the controller determines a best cluster among the candidate clusters to which the client should connect for the communication session based on the measures of reachability to the candidate clusters, and selects a media node in the best cluster. The controller sends to the client device contact information for the media node to enable the client device to connect to the media node for the communication session.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R, R1-R5, k, m, n, and q are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues.

Abstract: Presented herein are methods for dynamic management of names and of named-based requests for media flows in an Information-Centric Network (ICN)-based real-time communication system. The use of different naming schemes on contribution segments and on distribution segments in such architectures results in an effective low latency and scalable communication model based on the notion of active speakers regardless of the underlying mapping between active speakers and participants controlled by the media bridge. Operations are performed both at client side and at media bridge side to dynamically manage binding of names to speakers, while minimizing overhead and complexity of operations involved by a change of active speaker/quality/layout.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I): where the substituents R, R1-R5, k, m, n, and q are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R1-R10, X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.